Isis And Aegerion: Investor Sentiment Ahead Of FDA Panels
Investors have rewarded one of these biotechs with lipid-lowering agents under review, while punishing the other. That’s despite the expectation that both could be approved soon.
You may also be interested in...
Biogen has agreed to pay an upfront and milestones for an option to license Isis' Phase I antisense compound to treat a rare spinal disorder.
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?
An estimated 400 million people globally are infected with hepatitis B, which can result in liver cancer and cirrhosis. Recent advances in RNA and other technologies may provide movement toward a cure, but it’s not clear yet if the biopharma industry will find the economics motivating enough for an all-out effort.